Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of genetically engineered mouse EGFR positive glioblastoma tumors with PDGFRA and GAL-1 positive and negative populations

ABSTRACT: RNA-seq of genetically engineered mouse EGFR positive glioblastoma tumors with PDGFRA and GAL-1 positive and negative populations

PROVIDER: PRJNA802215 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17836880.fastq.gz	Fastqsanger.gz
	SRR17836881.fastq.gz	Fastqsanger.gz
	SRR17836882.fastq.gz	Fastqsanger.gz
	SRR17836883.fastq.gz	Fastqsanger.gz
	SRR17836884.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNA-seq of genetically engineered mouse EGFR positive glioblastoma tumors with PDGFRA and GAL-1 positive and negative populations

Project description:RNA-seq of genetically engineered mouse EGFR positive glioblastoma tumors flow cytometry sorted into PDGFRA and GAL-1 positive and negative populations.

2022-04-06 | GSE195813 | GEO

Expression profiles of Ecrg4hetero beta-gal positive neurosphere and Ecrg4hetero beta-gal positive VZ/SVZ

Project description:Expression profiles of Ecrg4hetero beta-gal positive neurosphere and Ecrg4hetero beta-gal positive VZ/SVZ

| PRJNA493799 | ENA

Characterization of circulating PDGFRa positive cells in fetus

Project description:Characterization of circulating PDGFRa positive cells in fetus

| PRJNA520915 | ENA

microRNA data in human EGFR positive versus EGFR negative colorectal cancer tissues

Project description:microRNA data in human EGFR positive versus EGFR negative colorectal cancer tissues

| PRJNA473846 | ENA

RNA-seq of wild-type, Gal-1 knockout, Gal-3 knockout and Gal-1/Gal-3 double knockout mouse embryonic stem cells (mESC) deprived of LIF for 7 days

Project description:Galectin-1 (Gal-1) and Galectin-3 (Gal-3) are conserved carbohydrate-binding proteins that also display RNA-binding activity. We generated mouse embryonic stem cells (mESC) constitutively depleted of Gal-1 and/or Gal-3 using CRISPR-Cas9, and assessed the transcriptomic effects of the individual or concomitant depletion of Gal-1 and Gal-3 in mESCs differentiated by deprivation of the leukaemia inhibitory factor (LIF) for 7 days. Wild-type cells were employed as control.

2023-05-27 | E-MTAB-9262 | biostudies-arrayexpress

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer

Project description:This SuperSeries is composed of the following subset Series: GSE36324: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-HCC1954] GSE36325: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm] GSE36326: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-SKBR3] Refer to individual Series

2012-10-22 | E-GEOD-36327 | biostudies-arrayexpress

RNAseq of murine CT26 cell line -WT and gal-9-KO - in vitro

Project description:A number of studies have reported evidence of positive or negative contributions of galectin-9 (gal-9) to human and experimental malignancies. Some clinical observations and in vitro experiments suggest that cell-associated gal-9 has anti-metastatic effects. On the other hand, extra-cellular gal-9 consistently enhances tumor immune escape. The aim of this experiment is to study the impact of gal-9 gene invalidation in the colon carcinoma cell line CT26, in vitro.

2020-09-20 | E-MTAB-9559 | biostudies-arrayexpress

Vibrio harveyi strain:Gal 88 | isolate:Gal 88

Project description:Vibrio harveyi strain:Gal 88 | isolate:Gal 88 Genome sequencing

| PRJNA763340 | ENA

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-SKBR3]

Project description:EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.

2012-10-22 | GSE36326 | GEO

Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm]

Project description:EGFR-inhibition is required for targeted therapies of EGFR high/ERBB2 positive breast cancer. Approximately 30% of human ERBB2 positive breast tumors also express EGFR.

2012-10-22 | GSE36325 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data